Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy

Neurona Therapeutics announced the presentation of a clinical case study from the initial dose cohort of the Phase I/II first-in-human epilepsy clinical trial of its lead program, NRTX-1001.